William Blair & Company’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

William Blair & Company’s Portfolio PRVL Stock Details PRVL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-15,455	Closed	-$357K	–	1935
2020 Q4	$357K	Buy	+15,455	New	+$196K	﹤0.01%	1191

William Blair & Company's PRVL Position: Q1 2021 in Review

William Blair & Company sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 15,455 shares — an estimated $357K sold.

William Blair & Company first reported a position in PRVL in Q4 2020 and held it in 1 quarter. The position peaked at $357K in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

William Blair & Company reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
William Blair & Company sold 15,455 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $357K.
William Blair & Company first reported a position in Prevail Therapeutics Inc. Common Stock in Q4 2020 and held it in 1 quarter.
William Blair & Company's Prevail Therapeutics Inc. Common Stock position peaked at $357K in Q4 2020.
0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on William Blair & Company's 13F filing for Q1 2021, filed 13 May 2021.